Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
AssigneesThe Regents of the University of California, Xenon Pharmaceuticals Inc.
InventorsTomas Ganz, Lan Lin, Yigal P. Goldberg
Life of this patent
Estimating the term…
Abstract
Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.
Claims7
A method of decreasing hepcidin production or suppressing hepcidin mRNA levels in a mammalian subject which comprises administering to the mammalian subject at least one soluble mammalian hemojuvelin protein.
Dependencies are inferred from the claim text.